GDS Wealth Management trimmed its position in UnitedHealth Group by 10.7% during the third quarter, selling 5,297 shares to end the period with 44,252 shares valued at $15.28 million. This move contributes to a broader pattern of portfolio rebalancing: LFA Lugano Financial Advisors established a new $25,000 stake in Q2, Sagard Holdings added $29,000, Grey Fox Wealth Advisors entered with $33,000, and Islay Capital Management initiated a $31,000 position. Riggs Asset Management notably boosted its holding by 69.4%, acquiring an additional 43 shares for a total of 105 shares worth $33,000. Institutional ownership remains high at 87.86%, underscoring the stock’s significance in diversified portfolios.

A series of bullish analyst actions has bolstered investor confidence. Jefferies raised its price objective from $317 to $409 and reaffirmed a Buy rating, while Goldman Sachs initiated coverage with a Buy rating and a $406 target. UBS increased its target from $378 to $430, Piper Sandler adjusted its objective modestly from $423 to $417 and maintained an Overweight stance, and Mizuho lifted its target from $300 to $430 with an Outperform rating. Collectively, one analyst rates the stock as Strong Buy, seventeen as Buy, nine as Hold and two as Sell, resulting in a consensus Moderate Buy and an average target of $386.33.

In the latest quarter, earnings per share of $2.92 exceeded consensus by $0.05, while revenue of $113.16 billion narrowly missed projections by $0.03 billion. The company reported a net margin of 4.04%, return on equity of 19.23% and 12.2% year-over-year revenue growth. Balance-sheet metrics feature a current ratio of 0.82, debt-to-equity of 0.71, a P/E ratio of 18.6 and a PEG of 2.15. The board declared a quarterly dividend of $2.21, translating to an $8.84 annual payout and a 2.5% yield, backed by a payout ratio below 50%. These factors underpin a stable free cash flow profile and reinforce management’s commitment to returning capital to shareholders.